Remove Antibody Remove Genotype Remove HR Remove Medicine
article thumbnail

AstraZeneca lung and breast cancer data at WCLC and ESMO.

The Pharma Data

AstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021.

Trials 52
article thumbnail

TrodelvyĀ®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

months with chemotherapy (HR: 0.43; 95% CI: 0.35-0.54; months (HR: 0.51; 95% CI: 0.41-0.62; The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. Medicines targeting these receptors therefore are not typically effective in treating TNBC. months from 1.7

HR 52
article thumbnail

TrodelvyĀ® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, an oncologist at New York-Presbyterian/Weill Cornell Medical Center and principal investigator of the TROPHY study. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines. About Trodelvy.